Sort   by:  
 Page size 
ProteomicsPharmacological Targeting of Casein Kinase 1δ Suppresses Oncogenic NRAS-Driven Melanoma
Activating mutations in NRAS account for 20-30% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS mutations ...
ORGANISM(S): Homo sapiens (Human) 
2024-09-20 | PXD046277 | Pride
Oncogenic nras melanomagenesis  melanoma progression ck1δ  usp46. 
ProteomicsPharmacological Targeting of Casein Kinase 1δ Suppresses Oncogenic NRAS-Driven Melanoma
Activating mutations in NRAS account for 15-20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS mutations ...
ORGANISM(S): Homo sapiens (Human) 
2024-09-19 | PXD051431 | Pride
Nras melanoma 
TranscriptomicsBRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
Prediction of outcome for melanoma patients with surgically-resected macroscopic nodal metastases is very imprecise. We performed a comprehensive clinicopathologic assessment of fresh-frozen macroscopic nodal metastases and the preceding primary melanoma, somatic mutation profiling and gene expressi...
ORGANISM(S): Homo sapiens 
2013-12-10 | E-GEOD-53118 | biostudies-arrayexpress
ProteomicsMelanoma NRAS - Cooperative induction of apoptosis in nras mutant melanoma by inhibition of mek and rock
In the present work we propose a new therapy for NRAS mutant melanoma. Simultaneous inhibition of MEK and ROCK caused induction of BimEL , PARP, and Puma, and hence apoptosis. In vivo, MEK and ROCK inhibition suppressed growth of established tumors. Our findings warrant clinical investigation of the...
ORGANISM(S): Homo sapiens (Human) 
2015-03-11 | PXD000528 | Pride
Phosphoproteome Melanoma Wholeproteome Nras 
TranscriptomicsMicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma
In order to improve our understanding of microRNA (miRNA) deregulation in melanoma development and possible consequences for patient survival, miRNA expression profiles were determined, using an array based approach, in melanoma tumors, melanoma cell lines and normal melanocytes. Differentially expr...
ORGANISM(S): Homo sapiens 
2010-04-21 | E-GEOD-19387 | biostudies-arrayexpress
OtherCooperative induction of apoptosis in nras mutant melanoma by inhibition of mek and rock
Data from ProteomeXchange, PXD ID: PXD000528. Experiment: GM_NKI_NRAS_Phospho_Mix2, file: OR9_20130426_GM_NKI_NRAS_Phospho_Mix2_repl1_ReRunFr10.mzml. Published as part of Pigment Cell Melanoma Res. 2015 Feb 28 . From the Abstract: {{i}} No effective targeted therapy is currently available for NRAS ...
ORGANISM(S): Homo_sapiens_viruses, Human 
GPM32320014056 | GPMDB
Resource Reanalysis 
ProteomicsData independent MS phenotyping of melanoma tissue specimens
Phenotyping of Stage III BRAF or NRAS mutant melanoma tissue specimens to predict drug response and patient survival
ORGANISM(S): Homo sapiens (Human) 
2018-10-11 | PXD007083 | Pride
Human Melanoma Swath Drug resistance 
ProteomicsNitrosylation-mediated regulation of MEK-ERK signaling in the NRAS-mutant melanoma
NRAS activating mutations occur in 15-25% of melanoma patients. However, this subtype is more aggressive and refractory to current treatment modalities, including targeted MEK inhibitors, immunotherapies, and the recently emerging RAS inhibitors. Accordingly, identifying novel therapeutic targets an...
ORGANISM(S): Homo sapiens (Human) 
2025-05-02 | PXD050244 | Pride
Nitrosylation Signaling Cancer Melanoma Map kinase 
TranscriptomicsTranscription profiling of different human melanoma cells in response to 5-aza-deoxycytidine
(subset of yale_halaban_skinspore_1) expression analysis in response to 5-aza-deoxycytidine and normal melanocytes versus melanoma.
ORGANISM(S): Homo sapiens 
2010-01-18 | E-MTAB-185 | biostudies-arrayexpress
TranscriptomicsGene expression profiling of oncogenic NRAS driven mouse melanomas that have developed resistance to NRAS withdrawal
Targeted therapies have the potential to revolutionize cancer care by providing personalized treatment strategies that are less toxic and more effective but it is clear that for most solid tumors suppression of a single target is not sufficient to prevent development of resistance. A powerful method...
ORGANISM(S): Mus musculus 
2014-10-31 | E-GEOD-51906 | biostudies-arrayexpress
Sort   by:  
 Page size